At a glance
- Originator Merck & Co
- Class Antibacterials; Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 15 Jun 2001 Preclinical development for Bacterial infections in USA (Unknown route)
- 04 Aug 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 07 Aug 1996 New profile